TEST BANK Pharmacotherapeutics
for Advanced Practice Nurse
Prescribers, 6th Edition Author: Teri
EXAM
1. An APRN in a state that requires collaborative practice
agreements is evaluating whether she may independently change
a controlled opioid prescription dose for a chronic pain patient.
Which is the MOST appropriate first step before making any
prescription change?
A. Increase the dose if the patient reports higher pain without
checking the agreement.
B. Review the state-specific scope-of-practice regulations and
the collaborative agreement terms.
C. Change the prescription and notify the collaborating
physician afterward.
D. Refer the patient to a pain clinic and avoid changing
prescriptions.
Correct Answer: B. Review the state-specific scope-of-practice
regulations and the collaborative agreement terms.
Rationale: APRNs must follow state scope-of-practice laws and
any collaborative agreement provisions before altering controlled
substance prescriptions. This step is critical to prevent legal or
regulatory violations and ensures safe, authorized prescribing.
,Acting without checking requirements (option A) risks unlawful
prescribing and professional discipline. Retroactive notification
(option C) does not substitute for required prior authorization
under many state regulations. While referral (option D) is
sometimes appropriate, it’s not the first step when addressing a
prescribing decision for a current patient.
2. A newly licensed Nurse Practitioner (NP) is preparing to
prescribe medication for the first time. Which foundational
principle should be the NP's primary guide?
A. Cost-effectiveness of the medication for the average
patient.
B. Protocols used by other prescribers in the same specialty.
C. Clinical evidence and patient-specific factors.
D. The patient's expressed preference for a specific treatment.
Correct Answer: C. Clinical evidence and patient-specific
factors.
Rationale: Rational drug selection and prescribing are grounded
in the application of pharmacologic evidence integrated with a
comprehensive patient assessment, including diagnosis,
comorbidities, and individual characteristics. While cost (option A)
is a practical consideration, it is not the primary guiding principle
over clinical evidence. Following protocols without critical thinking
(option B) does not constitute independent, evidence-based
prescribing. Patient preference (option D) is important and should
be incorporated through shared decision-making, but it does not
override clinical evidence and safety.
3. Nurse practitioner prescriptive authority is regulated by:
, A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
Correct Answer: C. The State Board of Nursing for each state.
Rationale: Prescriptive authority for nurse practitioners is
governed at the state level by each state's Board of Nursing.
These boards set the requirements and scope for NP practice,
which varies from state to state. The U.S. Drug Enforcement
Administration (DEA) regulates controlled substances at the
federal level but does not grant prescriptive authority.
4. The benefits to the patient of having an Advanced Practice
Registered Nurse (APRN) prescriber include:
A. Nurses know more about pharmacology than other
prescribers because they take it both in their basic nursing
program and in their APRN program.
B. Nurses care for the patient from a holistic approach and
include the patient in decision-making regarding their care.
C. APRNs are less likely to prescribe narcotics and other
controlled substances.
D. APRNs are able to prescribe independently in all states,
whereas a physician’s assistant needs to have a physician
supervising their practice.
Correct Answer: B. Nurses care for the patient from a holistic
approach and include the patient in decision-making
regarding their care.
, Rationale: A key benefit of APRN prescribers is their holistic
approach to patient care, which includes the patient in the
decision-making process regarding their treatment. This is a
cornerstone of advanced practice nursing. While APRNs have
strong pharmacology knowledge (option A), it’s not necessarily
superior; the focus is on the application of that knowledge. The
statement about narcotics (option C) is a generalization, and
prescribing independence (option D) varies significantly by state,
as not all states grant full independent practice.
5. The process for choosing an effective drug for a disorder
includes:
A. Asking the patient what drug they think would work best
for them
B. Consulting nationally recognized guidelines for disease
management
C. Prescribing medications that are available as samples
before writing a prescription
D. Following U.S. Drug Enforcement Administration
guidelines for prescribing
Correct Answer: B. Consulting nationally recognized
guidelines for disease management.
Rationale: Evidence-based practice requires consulting clinical
practice guidelines (e.g., from the AHA, ADA, or USPSTF) to select
the most effective and safe pharmacotherapy for a specific
disorder. These guidelines are based on the best available
research. Patient preference (option A) is considered but not the
primary basis for selection. Prescribing based on samples (option
C) may not align with the best evidence. While important, DEA
for Advanced Practice Nurse
Prescribers, 6th Edition Author: Teri
EXAM
1. An APRN in a state that requires collaborative practice
agreements is evaluating whether she may independently change
a controlled opioid prescription dose for a chronic pain patient.
Which is the MOST appropriate first step before making any
prescription change?
A. Increase the dose if the patient reports higher pain without
checking the agreement.
B. Review the state-specific scope-of-practice regulations and
the collaborative agreement terms.
C. Change the prescription and notify the collaborating
physician afterward.
D. Refer the patient to a pain clinic and avoid changing
prescriptions.
Correct Answer: B. Review the state-specific scope-of-practice
regulations and the collaborative agreement terms.
Rationale: APRNs must follow state scope-of-practice laws and
any collaborative agreement provisions before altering controlled
substance prescriptions. This step is critical to prevent legal or
regulatory violations and ensures safe, authorized prescribing.
,Acting without checking requirements (option A) risks unlawful
prescribing and professional discipline. Retroactive notification
(option C) does not substitute for required prior authorization
under many state regulations. While referral (option D) is
sometimes appropriate, it’s not the first step when addressing a
prescribing decision for a current patient.
2. A newly licensed Nurse Practitioner (NP) is preparing to
prescribe medication for the first time. Which foundational
principle should be the NP's primary guide?
A. Cost-effectiveness of the medication for the average
patient.
B. Protocols used by other prescribers in the same specialty.
C. Clinical evidence and patient-specific factors.
D. The patient's expressed preference for a specific treatment.
Correct Answer: C. Clinical evidence and patient-specific
factors.
Rationale: Rational drug selection and prescribing are grounded
in the application of pharmacologic evidence integrated with a
comprehensive patient assessment, including diagnosis,
comorbidities, and individual characteristics. While cost (option A)
is a practical consideration, it is not the primary guiding principle
over clinical evidence. Following protocols without critical thinking
(option B) does not constitute independent, evidence-based
prescribing. Patient preference (option D) is important and should
be incorporated through shared decision-making, but it does not
override clinical evidence and safety.
3. Nurse practitioner prescriptive authority is regulated by:
, A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
Correct Answer: C. The State Board of Nursing for each state.
Rationale: Prescriptive authority for nurse practitioners is
governed at the state level by each state's Board of Nursing.
These boards set the requirements and scope for NP practice,
which varies from state to state. The U.S. Drug Enforcement
Administration (DEA) regulates controlled substances at the
federal level but does not grant prescriptive authority.
4. The benefits to the patient of having an Advanced Practice
Registered Nurse (APRN) prescriber include:
A. Nurses know more about pharmacology than other
prescribers because they take it both in their basic nursing
program and in their APRN program.
B. Nurses care for the patient from a holistic approach and
include the patient in decision-making regarding their care.
C. APRNs are less likely to prescribe narcotics and other
controlled substances.
D. APRNs are able to prescribe independently in all states,
whereas a physician’s assistant needs to have a physician
supervising their practice.
Correct Answer: B. Nurses care for the patient from a holistic
approach and include the patient in decision-making
regarding their care.
, Rationale: A key benefit of APRN prescribers is their holistic
approach to patient care, which includes the patient in the
decision-making process regarding their treatment. This is a
cornerstone of advanced practice nursing. While APRNs have
strong pharmacology knowledge (option A), it’s not necessarily
superior; the focus is on the application of that knowledge. The
statement about narcotics (option C) is a generalization, and
prescribing independence (option D) varies significantly by state,
as not all states grant full independent practice.
5. The process for choosing an effective drug for a disorder
includes:
A. Asking the patient what drug they think would work best
for them
B. Consulting nationally recognized guidelines for disease
management
C. Prescribing medications that are available as samples
before writing a prescription
D. Following U.S. Drug Enforcement Administration
guidelines for prescribing
Correct Answer: B. Consulting nationally recognized
guidelines for disease management.
Rationale: Evidence-based practice requires consulting clinical
practice guidelines (e.g., from the AHA, ADA, or USPSTF) to select
the most effective and safe pharmacotherapy for a specific
disorder. These guidelines are based on the best available
research. Patient preference (option A) is considered but not the
primary basis for selection. Prescribing based on samples (option
C) may not align with the best evidence. While important, DEA
